1995 年 5 巻 1 号 p. 58-118
This study has been undertaken under the auspices and support of the Health Care Science Institute in Tokyo during June-September 1994. It considers the strategies of the three largest Swiss pharmaceutical companies in adapting to current changes in the global pharmaceutical industry. The global industry issues and trends are identified; the corporate portraits of Roche, Ciba, and Sandoz and their current strategic positions presented. The diverging approaches of the Swiss pharmaceutical giants indicate to the reconfiguration of the global pharmaceutical industry currently under way. The study concludes with a commentary on the emerging strategic capabilities of global pharmaceutical companies.